Baseline neutrophil-to-lymphocyte ratio in patients with advanced melanoma treated with immune checkpoint inhibitors.

Machet, L; Zaragoza, J; Finon, A; Garnier, M; Maillard, H; Caille, A

Machet, L; Zaragoza, J; Finon, A; Garnier, M; Maillard, H; Caille, A.

Afiliação

Machet L; Inserm U1253, University of Tours, Tours, France.
Zaragoza J; Department of Dermatology, Tours, France.
Finon A; Department of Dermatology, CHR Orléans, Orléans, France.
Garnier M; Department of Dermatology, CHR Orléans, Orléans, France.
Maillard H; Department of Dermatology, Tours, France.
Caille A; Department of Dermatology, CH Le Mans, Le Mans, France.

Br J Dermatol ; 179(1): 224, 2018 07.

Article em En | MEDLINE | ID: mdl-29660775

Assuntos

Melanoma; Nivolumabe; Humanos; Imunoterapia; Lactato Desidrogenases; Linfócitos; Neutrófilos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Nivolumabe / Melanoma Limite: Humans Idioma: En Revista: Br J Dermatol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: França

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google